3 results
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
The primary objective of the study is to quantitatively determine the PK (distribution, metabolism, and excretion) of 14C-vosaroxin and its metabolites in patients with advanced solid tumors.The secondary objective is to evaluate safety and…
Primary Objective:Double-blind period : Evaluate the effect of SRP-4045 and SRP-4053 (combined-active group) compared to placebo on ambulation, endurance, and muscle function, as measured by the 6MWTSecondary Objectives:- Double-blind period:…